Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE ‐Assessed Meta‐Analysis of Randomized Trials With Trial Sequential Evidence
Endocrinology, Diabetes & Metabolism · 2026-05 · 9 (3)
DOI: 10.1002/edm2.70220 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 20.04.2026. Verfasst von Ahmed Emara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Cardiovascular Diseases, Oligonucleotides. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hypertriglyceridemia is a widely prevalent disorder of lipid metabolism that increases the risk of cardiovascular disease and pancreatitis, and it often remains difficult to control even with standard treatments. Olezarsen, an antisense oligonucleotide that targets apolipoprotein C‐III (ApoC‐III), offers a new and promising option for lowering triglyceride levels.
Methods
A systematic search of PubMed, Scopus, Web of Science, and Cochrane was conducted through September 2025 to identify randomized controlled trials (RCTs) comparing olezarsen with placebo in adults with hypertriglyceridemia at high cardiovascular risk. Dichotomous outcomes were analysed as risk ratios (RRs) and continuous outcomes as percentage mean differences (MDs), both with 95% confidence intervals (CIs).
Results
Four RCTs ( n = 1615 patients) were included. Olezarsen significantly reduced triglycerides (MD −47.71%, 95% CI −56.78 to −38.64, p < 0.0001), non‐HDL‐C (MD −22.11%, 95% CI −28.48 to −15.75, p < 0.0001), ApoC‐III (MD −68.93%, 95% CI −77.54 to −60.31, p < 0.0001), VLDL‐C (MD −48.52%, 95% CI −57.16 to −39.87, p < 0.0001), and ApoB (MD −10.67%, 95% CI −16.83 to −4.51, p = 0.0007), while increasing HDL‐C (MD 35.13%, 95% CI –27.30 to –42.96, p < 0.0001). LDL‐C showed no significant change. The risks of any or serious adverse events were comparable to placebo. Olezarsen was associated with fewer acute pancreatitis events ( p = 0.035) but higher rates of liver enzyme elevations ≥ 3× ULN ( p = 0.046).
Conclusions
Olezarsen demonstrated consistent improvements in triglycerides and other atherogenic lipid parameters with an overall acceptable safety profile. These findings suggest that olezarsen may be a useful adjunct option for patients with persistent hypertriglyceridemia despite standard therapy. Further large‐scale and long‐term studies are needed to confirm its cardiovascular and safety outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
- Clinical Research Department, El-Gomhoria General Hospital, MOHP, Alexandria, Egypt.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Arabian Gulf University, Manama, Kingdom of Bahrain.
- Kuwait Institute for Medical Specializations, Kuwait City, Kuwait.
ORCID-Profile: Ahmed Emara, Ameer Awashra, Ahmed Farid Gadelmawla, Abdullah M Alharran, Abdalhakim Shubietah
Zitieren
APA
Emara, A., Awashra, A., Aboeldahab, H., Gadelmawla, A. F., Abdul-Hafez, H. A., Alharran, A. M., Alsubaiei, A. A., AlRumaihi, M. J., Albuhmaid, S. A., & Shubietah, A. (2026). Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE ‐Assessed Meta‐Analysis of Randomized Trials With Trial Sequential Evidence. Endocrinology, Diabetes & Metabolism, 9(3). https://doi.org/10.1002/edm2.70220
Vancouver
Emara A, Awashra A, Aboeldahab H, Gadelmawla AF, Abdul-Hafez HA, Alharran AM, et al. Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE ‐Assessed Meta‐Analysis of Randomized Trials With Trial Sequential Evidence. Endocrinology, Diabetes & Metabolism. 2026;9(3). doi:10.1002/edm2.70220
BibTeX
@article{Emara2026,
author = {Emara, Ahmed and Awashra, Ameer and Aboeldahab, Heba and Gadelmawla, Ahmed Farid and Abdul-Hafez, Hamza A and Alharran, Abdullah M and Alsubaiei, Amal A and AlRumaihi, Muneera Jasim and Albuhmaid, Sara Ahmed and Shubietah, Abdalhakim},
title = {Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE ‐Assessed Meta‐Analysis of Randomized Trials With Trial Sequential Evidence},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {3},
doi = {10.1002/edm2.70220}
}
EUVIMED